SEARCH:   Advanced

Blood, 15 August 2007, Vol. 110, No. 4, pp. 1283-1290. Prepublished online as a Blood First Edition Paper on April 24, 2007; DOI 10.1182/blood-2007-02-074252. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-02-074252v1 110/4/1283    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kreil, S. Articles by Cross, N. C. P. Search for Related Content PubMed PubMed Citation Articles by Kreil, S. Articles by Cross, N. C. P. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia Sebastian Kreil1,2, Markus Pfirrmann3,4, Claudia Haferlach5, Katherine Waghorn1, Andrew Chase1, Rüdiger Hehlmann2, Andreas Reiter2, Andreas Hochhaus2, Nicholas C. P. Cross1, for the German Chronic Myelogenous Leukemia (CML) Study Group 1 Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom; 2 III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität, Heidelberg, Germany; 3 Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany; 4 Gesellschaft für Informationsverarbeitung und Statistik in der Medizin e.V., Munich, Germany and 5 MLL (Münchner Leukämielabor), Munich, Germany Derivative chromosome 9 deletions are seen in 10% to 15% of patients with chronic myelogenous leukemia and have been associated with a poor prognosis; however, no studies have been performed in the context of a randomized clinical trial. We developed a DNA-based deletion screen and investigated 339 chronic phase patients treated with interferon- as first-line therapy in 3 controlled German studies with a median observation time of 7 years. Deletions were detected in pretreatment DNA of 59 of 339 (17%) patients. Of these, 21 spanned the ABL/BCR junction and 38 were centromeric (n = 20) or telomeric (n = 18) of the breakpoint. There was no significant difference in overall survival between deleted and nondeleted patients. Patients with breakpoint-spanning deletions had poorer survival compared with patients without deletions (4.7 versus 7.8 years; P = .003), but this was not significant when censored at allogeneic stem cell transplantation (n = 129) or imatinib (n = 62) treatment in the first chronic phase (P = .078). Unexpectedly, deletions that did not span the breakpoint were associated with improved survival compared with cases without deletions (P = .001). Multiple Cox regression analysis indicated that deletion status (P = .007), age (P = .018), and spleen enlargement (P < .001) were significant independent indicators of survival and confirmed that only deletions spanning the ABL/BCR breakpoint were associated with an adverse prognosis (P = .039). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020